This simple injection may one day help people recover more safely and fully after a heart attack.

Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) have developed a world-first portable point-of-care test that detects four common sexually transmitted infections at once, in under an hour.

A Japanese research team has demonstrated in rat experiments that stem cells from human primary tooth pulp may help treat chronic-phase cerebral palsy.

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block their attack, and fuel tumor growth.

A new study by researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain metastases, one of the most challenging and deadly complications of lung cancer.

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically “cold,” meaning they do not attract enough immune cells to mount a strong attack.

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions. Using mice with human antibody genes, the research team developed new genetically human monoclonal antibodies that prevent two key antigens on the surface of the virus from binding to and entering human immune cells.

Researchers at the Icahn School of Medicine at Mount Sinai have reported promising findings that may help redefine treatment for patients with muscle-invasive bladder cancer, a potentially aggressive form of the disease traditionally treated with surgical removal of the bladder. The study, published in the Proceedings of the National Academy of Sciences, demonstrates that ultra-sensitive testing of tumor-derived DNA in blood and urine may help identify patients who can safely preserve their bladder without compromising cancer outcomes.

A pioneering genetic test is improving early diagnosis and treatment for people with hereditary cancer caused by a genetic condition. The test, developed with the help of Newcastle University scientists, identifies specific signs in a person’s DNA that are characteristic of cancers linked with Lynch syndrome.

A research team investigating the use of the bacterium Listeria monocytogenes against colorectal cancer has discovered a way to build a modified version of Listeria as an oral vaccine to prime the immune system directly within the gut, where anti-tumor cells are then generated. Details of the work, led by Stony Brook immunologist Brian Sheridan, Ph.D., are published in the Journal for the ImmunoTherapy of Cancer.